Evaluation of the Efficacy of Vertistop® D and Vertistop® L in the Prevention of BPPV Recurrence
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
The study involves the evaluation of 3 groups of subjects (3-arm study). Patients diagnosed
with BPPV and "sufficient" serum concentrations of Vitamin D (>30 ng/mL, >75 nmol/L) at
baseline may be treated with 2 tablets per day (morning and evening) of Vertistop® L (
Alpha-lipoic acid, carnosine, zinc and curcumin) or untreated, on the basis of the
randomization criterion to which they will be assigned. Patients with Vitamin D "deficiency"
(<20 ng/mL, <50 nmol/L) or Vitamin D "insufficient" (20-30 ng/mL, 50-75 nmol/L) at baseline,
or subsequent follow-up, they will be treated for 2 months with Vertistop® D (alpha-lipoic
acid, carnosine and zinc, vitamin D3 and vitamins of the B complex) taking 1 tablet a day
(before meals).
The main purpose of the study is to evaluate, over a period of 6 months, the efficacy of
Vertistop® D and Vertistop® L supplementation in preventing recurrences of BPPV (Benign
Paroxysmal Positional Vertigo), in relation to blood levels of Vitamin D.